Department of Ophthalmology, The Second Affiliated Hospital of Fujian Medical University, Engineering Research Centre of Assistive Technology for Visual Impairment, Fujian Province University, No. 34 North Zhongshan Road, Quanzhou, 362000, Fujian Province, China.
Centre of Neurological and Metabolic Research, the Second Affiliated Hospital of Fujian Medical University, No. 34 North Zhongshan Road, Quanzhou, 362000, Fujian Province, China.
Stem Cell Res Ther. 2022 Jun 7;13(1):237. doi: 10.1186/s13287-022-02931-y.
Stem cell transplantation may improve visual acuity in patients with dry age-related macular degeneration. Herein, we aimed to summarise the evidence on the risks and benefits of stem cell transplantation for improving visual acuity, including the risk of adverse events.
Data were obtained from the PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials databases, and each database was interrogated from the date of inception until 19 March 2022. The rates of visual acuity outcomes and adverse events associated with stem cell transplantation were examined. All statistical analyses were conducted using Review Manager 5.4. The study was registered with PROSPERO (CRD 42022322902).
The analysis examined 10 studies (102 patients), including one and three, randomised and non-randomised clinical trials, and one and five, multicentre prospective and prospective clinical trials, respectively. Meta-analysis showed changes in best-corrected visual acuity in the study eyes after stem cell transplantation (6 months: risk ratio [RR] = 17.00, 95% confidence interval [CI] 6.08-47.56, P < 0.00001; 12 months: RR = 11.00, 95% CI 2.36-51.36, P = 0.002). Subgroup analysis showed that different stem cell types achieved better best-corrected visual acuity at post-operative 6 months, compared to that observed at baseline. Four cases of related ocular adverse events and no related systemic adverse events were reported.
This meta-analysis suggests that stem cell transplantation may improve best-corrected visual acuity in dry age-related macular degeneration, based on small sample sizes and fewer randomised controlled trials.
干细胞移植可能改善干性年龄相关性黄斑变性患者的视力。在此，我们旨在总结干细胞移植改善视力的风险和获益证据，包括不良事件风险。
数据来自 PubMed、EMBASE 和 Cochrane 对照试验中心注册库，每个数据库均从建库日期检索至 2022 年 3 月 19 日。检查了与干细胞移植相关的视力结果和不良事件的发生率。所有统计分析均使用 Review Manager 5.4 进行。该研究已在 PROSPERO（CRD 42022322902）注册。
分析纳入了 10 项研究（102 例患者），包括 1 项和 3 项随机和非随机临床试验，以及 1 项和 5 项多中心前瞻性和前瞻性临床试验。Meta 分析显示，干细胞移植后研究眼最佳矫正视力发生变化（6 个月：风险比 [RR] = 17.00，95%置信区间 [CI] 6.08-47.56，P < 0.00001；12 个月：RR = 11.00，95% CI 2.36-51.36，P = 0.002）。亚组分析显示，不同的干细胞类型在术后 6 个月时的最佳矫正视力优于基线时的视力。报告了 4 例与眼部相关的不良事件，无与全身相关的不良事件。
本荟萃分析表明，基于小样本量和较少的随机对照试验，干细胞移植可能改善干性年龄相关性黄斑变性的最佳矫正视力。
